Ana Ruiz-Garcia

Ana Ruiz-Garcia

Auto-generated profile, based on publicly available information

Ana Ruiz-Garcia

Gilead Sciences Foster City California USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2009 in The Lancet Oncology
Verified
Journal Article
Closed access
SFSandrine Faivre
Sandrine Faivre
EREric Raymond
Eric Raymond
EBEveline Boucher
Eveline Boucher
JDJean Douillard
Jean Douillard
HLHo Y Lim
Ho Y Lim
LCLi-Tzong Chen
Li-Tzong Chen

20 September 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SRSuresh S. Ramalingam
Suresh S. Ramalingam
FBFiona Blackhall
Fiona Blackhall
MKMaciej Krzakowski
Maciej Krzakowski
CBCarlos H. Barrios
Carlos H. Barrios
KPKeunchil Park
Keunchil Park
MBMichael Boyer
Michael Boyer
Purpose: This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non–small-cell lung cancer (NSCLC). Patients and Methods: Patients with NSCLC, Eastern Cooperative Oncology Group performance status 0 to 2, no prior HER-directed therapy, and one/two prior chemotherapy regimens received dacomitinib 45 mg or erlotinib 150 mg once daily. Results: One hundred eighty-eight patients were randomly assigned. Treatment arms were balanced for most clinical and molecular characteristics. Median progression-free survival (PFS; primary end point) was 2.86 months for patients treated with dacomitinib and 1.91 months for patients treated with erlotinib (hazard ratio [HR] = 0.66; 95% CI, 0.47 to 0.91; two-sided P = .012); in patients with KRAS wild-type tumors, median PFS was 3.71 months for patients treated with dacomitinib and 1.91 months for patients treated with erlotinib (HR = 0.55; 95% CI, 0.35 to 0.85; two-sided P = .006); and in patients with KRAS wild-type/EGFR wild-type tumors, median PFS was 2.21 months for patients treated with dacomitinib and 1.84 months for patients treated with erlotinib (HR = 0.61; 95% CI, 0.37 to 0.99; two-sided P = .043). Median overall survival was 9.53 months for patients treated with dacomitinib and 7.44 months for patients treated with erlotinib (HR = 0.80; 95% CI, 0.56 to 1.13; two-sided P = .205). Adverse event-related discontinuations were uncommon in both arms. Common treatment-related adverse events were dermatologic and gastrointestinal, predominantly grade 1 to 2, and more frequent with dacomitinib. Conclusion: Dacomitinib demonstrated significantly improved PFS versus erlotinib, with acceptable toxicity. PFS benefit was observed in most clinical and molecular subsets, notably KRAS wild-type/EGFR any status, KRAS wild-type/EGFR wild-type, and EGFR mutants.

3 July 2013 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
PDF file
WBW Byon
W Byon
MSMk Smith
Mk Smith
PCP Chan
P Chan
MTMa Tortorici
Ma Tortorici
SRS Riley
S Riley
CCC Cronenberger
C Cronenberger
This tutorial describes the development of a population pharmacokinetic (Pop PK) analysis guidance within Pfizer, which strives for improved consistency and efficiency, and a more systematic approach to model building. General recommendations from the Pfizer internal guidance and a suggested workflow for Pop PK model building are discussed. A description is also provided for mechanisms by which conflicting opinions were captured and resolved across the organization to arrive at the final guidance.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e51; doi:10.1038/psp.2013.26; advance online publication 3 July 2013

1 March 2004 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
Marival BermejoMarival Bermejo
Marival Bermejo
AAAlex Avdeef
Alex Avdeef
ARAna Ruiz
Ana Ruiz
Ricardo Nalda-MolinaRicardo Nalda-Molina
Ricardo Nalda-Molina
JRJeffrey A. Ruell
Jeffrey A. Ruell
VMVirginia Merino
Virginia Merino

1 February 2008 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
ARAna Ruiz-Garcia
Ana Ruiz-Garcia
Marival BermejoMarival Bermejo
Marival Bermejo
AMAaron Moss
Aaron Moss
VCVicente G. Casabo
Vicente G. Casabo
The aim of this current review is to summarize the present status of pharmacokinetics in Drug Discovery. The review is structured into four sections. The first section is a general overview of what we understand by pharmacokinetics and the different LADMET aspects: Liberation, Absorption, Distribution, Metabolism, Excretion, and Toxicity. The second section highlights the different computational or in silico approaches to estimate/predict one or several aspects of the pharmacokinetic profile of a discovery lead compound. The third section discusses the most commonly used in vitro methodologies. The fourth and last section examines the various approaches employed towards the pharmacokinetic assessment of discovery molecules; including all the LADME processes, discussing the different mathematical methodologies available to establish the PK profile of a test compound; what the main differences are and what should be the criteria for using one or another mathematical approach. The major conclusion of this review is that the use of the appropriate preclinical assays has a key role in the long‐term viability of a pharmaceutical company since applying the right tools early in discovery will play a key role in determining the company's ability to discover novel safe and effective therapeutics to patients as quickly as possible. © 2007 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 97:654–690, 2008

12 May 2010 in Investigational New Drugs
Verified
Journal Article
Open access
PDF file
Yung-Jue BangYung-Jue Bang
Yung-Jue Bang
YKYoon-Koo Kang
Yoon-Koo Kang
WKWon K. Kang
Won K. Kang
NBNarikazu Boku
Narikazu Boku
HCHyun Cheol Chung
Hyun Cheol Chung
ASAlberto Sobrero
Alberto Sobrero
Summary Purpose. This phase II, open-label, multicenter study assessed the oral, multitargeted, tyrosine kinase inhibitor sunitinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma who had received prior chemotherapy. Experimental design. Patients received sunitinib 50 mg/day on Schedule 4/2 (4 weeks on treatment, followed by 2 weeks off treatment). The primary endpoint was objective response rate; secondary endpoints included clinical benefit rate, duration of response, progression-free survival (PFS), overall survival (OS), pharmacokinetics, pharmacodynamics, safety and tolerability, and quality of life. Results. Of 78 patients enrolled, most had gastric adenocarcinoma (93.6%) and metastatic disease (93.6%). All were evaluable for safety and efficacy. Two patients (2.6%) had partial responses and 25 patients (32.1%) had a best response of stable disease for ≥6 weeks. Median PFS was 2.3 months (95% confidence interval [CI], 1.6–2.6 months) and median OS was 6.8 months (95% CI, 4.4–9.6 months). Grade ≥3 thrombocytopenia and neutropenia were reported in 34.6% and 29.4% of patients, respectively, and the most common non-hematologic adverse events were fatigue, anorexia, nausea, diarrhea, and stomatitis. Pharmacokinetics of sunitinib and its active metabolite were consistent with previous reports. There were no marked associations between baseline soluble protein levels, or changes from baseline, and measures of clinical outcome. Conclusions. The progression-delaying effect and manageable toxicity observed with sunitinib in this study suggest that although single-agent sunitinib has insufficient clinical value as second-line treatment for advanced gastric cancer, its role in combination with chemotherapy merits further study.